150 related articles for article (PubMed ID: 11897556)
1. Pi 3-kinase and its up- and down-stream modulators as potential targets for the treatment of type II diabetes.
Jiang G; Zhang BB
Front Biosci; 2002 Apr; 7():d903-7. PubMed ID: 11897556
[TBL] [Abstract][Full Text] [Related]
2. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.
Sasaoka T; Wada T; Tsuneki H
Pharmacol Ther; 2006 Dec; 112(3):799-809. PubMed ID: 16842857
[TBL] [Abstract][Full Text] [Related]
3. PTEN, but not SHIP2, suppresses insulin signaling through the phosphatidylinositol 3-kinase/Akt pathway in 3T3-L1 adipocytes.
Tang X; Powelka AM; Soriano NA; Czech MP; Guilherme A
J Biol Chem; 2005 Jun; 280(23):22523-9. PubMed ID: 15824124
[TBL] [Abstract][Full Text] [Related]
4. SHIP2: an emerging target for the treatment of type 2 diabetes mellitus.
Baumgartener JW
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):291-8. PubMed ID: 14683460
[TBL] [Abstract][Full Text] [Related]
5. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
6. Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors.
Freeburn RW; Wright KL; Burgess SJ; Astoul E; Cantrell DA; Ward SG
J Immunol; 2002 Nov; 169(10):5441-50. PubMed ID: 12421919
[TBL] [Abstract][Full Text] [Related]
7. Phosphatases as small-molecule targets: inhibiting the endogenous inhibitors of kinases.
Schmid AC; Woscholski R
Biochem Soc Trans; 2004 Apr; 32(Pt 2):348-9. PubMed ID: 15046606
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity.
Wada T; Sasaoka T; Funaki M; Hori H; Murakami S; Ishiki M; Haruta T; Asano T; Ogawa W; Ishihara H; Kobayashi M
Mol Cell Biol; 2001 Mar; 21(5):1633-46. PubMed ID: 11238900
[TBL] [Abstract][Full Text] [Related]
9. Lipid phosphatases as drug discovery targets for type 2 diabetes.
Lazar DF; Saltiel AR
Nat Rev Drug Discov; 2006 Apr; 5(4):333-42. PubMed ID: 16582877
[TBL] [Abstract][Full Text] [Related]
10. Requirement of phosphoinositide 3-kinase and Akt for interferon-beta-mediated induction of the beta-R1 (SCYB11) gene.
Rani MR; Hibbert L; Sizemore N; Stark GR; Ransohoff RM
J Biol Chem; 2002 Oct; 277(41):38456-61. PubMed ID: 12169689
[TBL] [Abstract][Full Text] [Related]
11. Dual role of SRC homology domain 2-containing inositol phosphatase 2 in the regulation of platelet-derived growth factor and insulin-like growth factor I signaling in rat vascular smooth muscle cells.
Sasaoka T; Kikuchi K; Wada T; Sato A; Hori H; Murakami S; Fukui K; Ishihara H; Aota R; Kimura I; Kobayashi M
Endocrinology; 2003 Sep; 144(9):4204-14. PubMed ID: 12933696
[TBL] [Abstract][Full Text] [Related]
12. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
Newton HB
Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
[TBL] [Abstract][Full Text] [Related]
13. The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases.
Backers K; Blero D; Paternotte N; Zhang J; Erneux C
Adv Enzyme Regul; 2003; 43():15-28. PubMed ID: 12791379
[No Abstract] [Full Text] [Related]
14. Restraining PI3K: mTOR signalling goes back to the membrane.
Harrington LS; Findlay GM; Lamb RF
Trends Biochem Sci; 2005 Jan; 30(1):35-42. PubMed ID: 15653324
[TBL] [Abstract][Full Text] [Related]
15. PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway.
Kim S; Domon-Dell C; Wang Q; Chung DH; Di Cristofano A; Pandolfi PP; Freund JN; Evers BM
Gastroenterology; 2002 Oct; 123(4):1163-78. PubMed ID: 12360479
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop.
Kim S; Domon-Dell C; Kang J; Chung DH; Freund JN; Evers BM
J Biol Chem; 2004 Feb; 279(6):4285-91. PubMed ID: 14623898
[TBL] [Abstract][Full Text] [Related]
17. Phosphoinositide signaling disorders in human diseases.
Pendaries C; Tronchère H; Plantavid M; Payrastre B
FEBS Lett; 2003 Jul; 546(1):25-31. PubMed ID: 12829232
[TBL] [Abstract][Full Text] [Related]
18. Impact of Src homology 2-containing inositol 5'-phosphatase 2 on the regulation of insulin signaling leading to protein synthesis in 3T3-L1 adipocytes cultured with excess amino acids.
Murakami S; Sasaoka T; Wada T; Fukui K; Nagira K; Ishihara H; Usui I; Kobayashi M
Endocrinology; 2004 Jul; 145(7):3215-23. PubMed ID: 15044364
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
Song K; Cornelius SC; Reiss M; Danielpour D
J Biol Chem; 2003 Oct; 278(40):38342-51. PubMed ID: 12876289
[TBL] [Abstract][Full Text] [Related]
20. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation.
Bouscary D; Pene F; Claessens YE; Muller O; Chrétien S; Fontenay-Roupie M; Gisselbrecht S; Mayeux P; Lacombe C
Blood; 2003 May; 101(9):3436-43. PubMed ID: 12506011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
